← Back to front page
Oceania · Regional markets · Stockhead

Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown

Published by Stockhead · Australia 1 h ago
Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown
Stockhead

Detailed summary

First participant completes 36-week randomised phase of Neurizon’s Phase 2/3 ALS Platform Trial as second drawdown of R&D financing facility ... Read More The post Neurizon…

A big week for Neurizon with a key trial milestone and further $3.7 million in R&D funding. Pic: Getty Images

Special Report: The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial has completed the 36-week randomised controlled trial (RCT) phase and transitioned into an Active Treatment Extension (ATE).

In a further boost, Neurizon Therapeutics (ASX:NUZ) has extended its R&D financing facility with the Dare Capital Loan Fund, completing a second drawdown of ~$3.7 million, secured against its estimated FY27 R&D Tax Rebate.

NUZ said the funding enabled it to better match its commitments in the platform trial, which represents its registrational study for NUZ-001 in amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND).

The trial is designed to generate clinical data to support potential regulatory submissions, including to the US Food and Drug Administration (FDA).

Part of the ALS Platform Trial, it is conducted in partnership with the Network of Excellence for ALS (NEALS), which evaluates multiple investigational drugs across more than 70 sites using shared infrastructure to streamline recruitment and accelerate development.

The first patient completing the RCT phase marks the next stage in progression of Regimen I of the trial.

Participants who complete the RCT phase at week 36 may voluntarily enter the ATE, where all participants receive investigational NUZ-001 regardless of their original treatment allocation.

The extension is designed to generate additional longer-term safety, tolerability, functional and biomarker data, complementing the clinical evidence collected during the RCT phase.

Opening of the article, excerpted from Stockhead. To read the rest, open the article on the publisher's site.

Read the full article on Stockhead Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading